Design, synthesis, and


Journal

Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203

Informations de publication

Date de publication:
Dec 2021
Historique:
entrez: 14 1 2021
pubmed: 15 1 2021
medline: 25 6 2021
Statut: ppublish

Résumé

Twelve novel analogs of STAT3 inhibitor BP-1-102 were designed and synthesised with the aim to modify hydrophobic fragments of the molecules that are important for interaction with the STAT3 SH2 domain. The cytotoxic activity of the reference and novel compounds was evaluated using several human and two mouse cancer cell lines. BP-1-102 and its two analogs emerged as effective cytotoxic agents and were further tested in additional six human and two murine cancer cell lines, in all of which they manifested the cytotoxic effect in a micromolar range. Reference compound S3I-201.1066 was found ineffective in all tested cell lines, in contrast to formerly published data. The ability of selected BP-1-102 analogs to induce apoptosis and inhibition of STAT3 receptor-mediated phosphorylation was confirmed. The structure-activity relationship confirmed a demand for two hydrophobic substituents, i.e. the pentafluorophenyl moiety and another spatially bulky moiety, for effective cytotoxic activity and STAT3 inhibition.

Identifiants

pubmed: 33440995
doi: 10.1080/14756366.2020.1871336
pmc: PMC7808747
doi:

Substances chimiques

Aminosalicylic Acids 0
Antineoplastic Agents 0
BP-1-102 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Sulfonamides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

410-424

Références

Eur J Med Chem. 2012 Feb;48:231-43
pubmed: 22209417
J Biol Chem. 2001 Nov 30;276(48):45443-55
pubmed: 11579100
ACS Med Chem Lett. 2013 Sep 08;4(11):1102-7
pubmed: 24900612
Clin Cancer Res. 2008 Dec 15;14(24):8228-35
pubmed: 19088040
ACS Chem Neurosci. 2016 Jun 15;7(6):767-75
pubmed: 26991242
Bioessays. 2001 Feb;23(2):161-9
pubmed: 11169589
ACS Chem Biol. 2016 Feb 19;11(2):308-18
pubmed: 26730496
ACS Med Chem Lett. 2010 Sep 07;1(9):454-9
pubmed: 24900231
Chem Biol. 2006 Nov;13(11):1235-42
pubmed: 17114005
Cold Spring Harb Protoc. 2016 Apr 01;2016(4):pdb.prot087379
pubmed: 27037069
Oncotarget. 2016 Mar 22;7(12):14458-75
pubmed: 26883108
Expert Opin Investig Drugs. 2009 May;18(5):555-68
pubmed: 19388873
Eur J Med Chem. 2017 Jan 5;125:538-550
pubmed: 27718470
Eur J Med Chem. 2013 Apr;62:498-507
pubmed: 23416191
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
ACS Med Chem Lett. 2010 Jul 13;1(8):371-5
pubmed: 24900220
BMC Genomics. 2017 Sep 11;18(1):718
pubmed: 28893190
Med Oncol. 2014 Apr;31(4):924
pubmed: 24652192
Science. 1997 Sep 12;277(5332):1630-5
pubmed: 9287210
Cancer Res. 1997 Aug 15;57(16):3325-30
pubmed: 9269988
Br J Radiol. 2005 Oct;78(934):945-7
pubmed: 16177019
Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9623-8
pubmed: 22623533
Cell. 1999 Aug 6;98(3):295-303
pubmed: 10458605
J Biol Chem. 2005 Sep 23;280(38):32979-88
pubmed: 16046414
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6
pubmed: 17463090
Br J Cancer. 2010 May 25;102(11):1592-9
pubmed: 20461084
Immunity. 1999 Jan;10(1):105-15
pubmed: 10023775
Bioorg Med Chem Lett. 2011 Sep 15;21(18):5605-9
pubmed: 21788134
Eur J Med Chem. 2020 Feb 1;187:111922
pubmed: 31810784
Int J Oncol. 2016 Mar;48(3):953-64
pubmed: 26718011
Semin Cancer Biol. 2020 Feb;60:41-56
pubmed: 31605750
Curr Cancer Drug Targets. 2007 Feb;7(1):91-107
pubmed: 17305481
Biochem Pharmacol. 2010 May 15;79(10):1398-409
pubmed: 20067773
Oncogene. 2007 Apr 12;26(17):2435-44
pubmed: 17043651
Oncogene. 2000 May 15;19(21):2468-73
pubmed: 10851045
Nat Rev Cancer. 2004 Feb;4(2):97-105
pubmed: 14964307
J Clin Invest. 1998 Oct 1;102(7):1385-92
pubmed: 9769331
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765

Auteurs

Patrik Oleksak (P)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Miroslav Psotka (M)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Marketa Vancurova (M)

Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

Olena Sapega (O)

Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

Jana Bieblova (J)

Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

Milan Reinis (M)

Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

David Rysanek (D)

Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

Romana Mikyskova (R)

Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

Katarina Chalupova (K)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

David Malinak (D)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Jana Svobodova (J)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Rudolf Andrys (R)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Helena Rehulkova (H)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Vojtech Skopek (V)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Pham Ngoc Lam (P)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Jiri Bartek (J)

Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Genome Integrity Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.

Zdenek Hodny (Z)

Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

Kamil Musilek (K)

Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH